Skip to main content

CORRECTION article

Front. Mol. Biosci., 24 April 2024
Sec. Molecular Diagnostics and Therapeutics
Volume 11 - 2024 | https://doi.org/10.3389/fmolb.2024.1298522

Corrigendum: Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project

This article is a correction to:

  1. Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project

    1. Read original article
Ana PeixotoAna Peixoto1Luís CirnesLuís Cirnes2Ana Luísa CarvalhoAna Luísa Carvalho3Maria Joo AndradeMaria João Andrade4 Maria Jos Brito Maria José Brito5Paula Borralho,Paula Borralho6,7Nuno CoimbraNuno Coimbra8Pedro M. BorralhoPedro M. Borralho9Ana Sofia CarneiroAna Sofia Carneiro10Lisandra CastroLisandra Castro11Lurdes Correia,Lurdes Correia10,12Maria Rita DionísioMaria Rita Dionísio9Carlos FariaCarlos Faria4Paulo FigueiredoPaulo Figueiredo13Ana GomesAna Gomes4Joana PaixoJoana Paixão10Manuela PinheiroManuela Pinheiro1Hugo PrazeresHugo Prazeres13Joana RibeiroJoana Ribeiro5Natlia SalgueiroNatália Salgueiro11Fernando. C Schmitt,Fernando. C Schmitt2,14Ftima Silva,,Fátima Silva4,15,16Ana Rita SilvestreAna Rita Silvestre6Ana Carla SousaAna Carla Sousa17Joana Almeida-TavaresJoana Almeida-Tavares10Manuel R. Teixeira, Manuel R. Teixeira1,18*Saudade Andr Saudade André3*Jose Carlos Machado, Jose Carlos Machado2,14*
  • 1Serviço de Genética Laboratorial, Instituto Português de Oncologia do Porto Francisco Gentil (IPO Porto), Porto, Portugal
  • 2IPATIMUP - Instituto de Patologia e Imunologia da Universidade do Porto, Porto, Portugal
  • 3Serviço de Anatomia Patológica, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal
  • 4Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
  • 5Unidade de Mama, Centro Clínico Champalimaud, Fundação Champalimaud, Lisboa, Portugal
  • 6Serviço de Anatomia Patológica, Hospital CUF Descobertas, Lisboa, Portugal
  • 7Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal
  • 8Serviço de Anatomia Patológica, Instituto Português de Oncologia do Porto Francisco Gentil (IPO Porto), Porto, Portugal
  • 9Novartis Farma - Produtos Farmacêuticos, S.A., Porto Salvo, Portugal
  • 10Serviço de Anatomia Patológica, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal
  • 11Departamento de Genética Molecular, SYNLAB Genética Médica, S.A., Porto, Portugal
  • 12Instituto de Anatomia Patológica, Lisboa, Portugal
  • 13Serviço de Anatomia Patológica, IPO Coimbra, Coimbra, Portugal
  • 14Faculdade de Medicina da Universidade do Porto, Porto, Portugal
  • 15Escola Superior de Tecnologia da Saúde de Coimbra, Coimbra, Portugal
  • 16Associação Portuguesa de Técnicas de Anatomia Patológica, Porto, Portugal
  • 17GenoMed – Diagnósticos de Medicina Molecular, S.A., Lisboa, Portugal
  • 18Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal

A Corrigendum on
Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project

by Peixoto A, Cirnes L, Carvalho AL, Andrade MJ, Brito MJ, Borralho P, Coimbra N, Borralho PM, Carneiro AS, Castro L, Correia L, Dionísio MR, Faria C, Figueiredo P, Gomes A, Paixão J, Pinheiro M, Prazeres H, Ribeiro J, Salgueiro N, Schmitt FC, Silva F, Silvestre AR, Sousa AC, Almeida-Tavares J, Teixeira MR, André S and Machado JC (2023). Front. Mol. Biosci. 10:1082915. doi: 10.3389/fmolb.2023.1082915

In the published article, there was an error in the author list, and author Nuno Coimbra was erroneously excluded. The corrected author list appears below.

Ana Peixoto1, Luís Cirnes2, Ana Luísa Carvalho3, Maria João Andrade4, Maria José Brito5, Paula Borralho6,7, Nuno Coimbra8, Pedro M. Borralho9, Ana Sofia Carneiro10, Lisandra Castro11, Lurdes Correia10,12, Maria Rita Dionísio9, Carlos Faria4, Paulo Figueiredo13, Ana Gomes4, Joana Paixão10, Manuela Pinheiro1, Hugo Prazeres13, Joana Ribeiro5, Natália Salgueiro11, Fernando C. Schmitt2,14, Fátima Silva4,15,16, Ana Rita Silvestre6, Ana Carla Sousa17, Joana Almeida-Tavares10, Manuel R. Teixeira1,18,*, Saudade André3,* and José Carlos Machado2,14,*

Following this correction, the Author contributions section should also be corrected to include the contribution of author Nuno Coimbra as follows: “JCM, SA, MRT, and PMB conceived the U-PIK Project. JCM, SA, MRT, PMB, FCS, MJA, MJB, PB, MRD, HP, NS, ACS, JAT participated in the study design. AP, LCi, ALC, MJA, MJB, PB, NC, ASC, LCa, LCo, CF, PF, AG, JP, MP, HP, JR, NS, FCS, FS, ARS, ACS, JAT performed the experimental work involved in sample preparation, DNA extraction and PIK3CA testing and reporting. JCM, SA and MRT were responsible for analyzing PIK3CA testing data from U-PIK testers, for reporting anonymized PIK3CA testing performance back to U-PIK testers, and also for the analysis of molecular reports. JCM, SA, MRT, PMB and AP edited the manuscript, drafted and written with editorial assistance of JCS (Acknowledgements). All authors read and approved the final manuscript.”

In the published article, there was an error regarding the affiliation for Nuno Coimbra, who was erroneously excluded from the author list and should have affiliation Serviço de Anatomia Patológica, Instituto Português de Oncologia do Porto Francisco Gentil (IPO Porto), Porto, Portugal.

The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: advanced breast cancer, ER+/HER2−, PIK3CA mutations, ring trial, validation, molecular pathology

Citation: Peixoto A, Cirnes L, Carvalho AL, Andrade MJ, Maria José Brito , Borralho P, Coimbra N, Borralho PM, Carneiro AS, Castro L, Correia L, Dionísio MR, Faria C, Figueiredo P, Gomes A, Paixão J, Pinheiro M, Prazeres H, Ribeiro J, Salgueiro N, Schmitt FC, Silva F, Silvestre AR, Sousa AC, Almeida-Tavares J, Teixeira MR, André S and Machado JC (2024) Corrigendum: Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project. Front. Mol. Biosci. 11:1298522. doi: 10.3389/fmolb.2024.1298522

Received: 21 September 2023; Accepted: 29 February 2024;
Published: 24 April 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Peixoto, Cirnes, Carvalho, Andrade, Maria José Brito, Borralho, Coimbra, Borralho, Carneiro, Castro, Correia, Dionísio, Faria, Figueiredo, Gomes, Paixão, Pinheiro, Prazeres, Ribeiro, Salgueiro, Schmitt, Silva, Silvestre, Sousa, Almeida-Tavares, Teixeira, André and Machado. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Manuel R. Teixeira, bWFudWVsLnRlaXhlaXJhQGlwb3BvcnRvLm1pbi1zYXVkZS5wdA==; Saudade André, c2FuZHJlQGlwb2xpc2JvYS5taW4tc2F1ZGUucHQ=; Jose Carlos Machado, am9zZW1AaTNzLnVwLnB0

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.